China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the launch of AdimFlu-S (QIS) in mainland China, marking it as the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older. The vaccine has been listed in 26 provinces and municipalities across the country, gearing up for commercialization. Clover anticipates that sales of AdimFlu-S will positively impact its financials starting in 2023, with significant growth contributions expected in 2024 and beyond.
AdimFlu-S (QIS): A Quadrivalent Split Inactivated Vaccine
AdimFlu-S (QIS) is a quadrivalent split inactivated vaccine designed for the prevention of influenza. It contains hemagglutinin from four influenza virus strains, comprising two A strains and two B strains. This quadrivalent composition enhances the vaccine’s effectiveness by providing broader coverage, which is crucial in a season when the prevalence of influenza B strains can vary. Compared to trivalent vaccines, AdimFlu-S (QIS) offers improved protection against a wider range of influenza strains.
Regulatory Approval and Market Potential
AdimFlu-S (QIS) received approval from the China National Medical Products Administration in January 2022 for use in individuals aged three years and older. With its launch, Clover Biopharmaceuticals is poised to expand its presence in the Chinese market, offering a valuable tool in the prevention of seasonal influenza.-Fineline Info & Tech
